Este documento presenta una lista de registros de medicamentos alopáticos expedidos durante el año 2011 por la Comisión de Autorización Sanitaria en México. Incluye el nombre distintivo y genérico de cada medicamento, su forma farmacéutica, el titular del registro y la fecha de vencimiento. En total se registraron 332 medicamentos de diferentes categorías terapéuticas.
Werfen Group es una corporación internacional de productos médicos de capital privado español formada por tres unidades de negocio: diagnóstico in vitro, dispositivos médicos para hospitales e instrumentos científicos. La compañía opera a nivel global a través de múltiples empresas y tiene presencia directa en 25 países y a través de distribuidores en 62 países.
abscess advanced trauma life support anterio advanced trauma life support antibiotics apically repositioned flap dental diseases dr dr shabeel drshabeel’s face eye trauma lidocaine anodontia management medical medicine misuse and abuse orthodontics teeth braces pharmacy pn preparation dental students for community based ed presentations s abscess abscess tooth active orthodonti shabeel shabeel"s shabeel’s shabeelpn trends of antimicrobial usage in dental practice View all
’s abscess abscess advanced trauma life support anterio abscess tooth active orthodontics adolescent advanced trauma life support aesthetic dentistry airway management alignment of teeth amalgam anesthesia in dentistry anesthetics in dentistry anterior open bite antibiotic resistanace antibiotics antibiotics and leukopenia aphthous ulcers apically repositioned flap apicoectomy appliances arch dental arch form orthodontics braces arch length orthodontics braces arch wire orthodontist braces ayurvedha baby teeth bloger boil books braces braces teeth cancer canker sore pain cavity preparation children community based learning congenitally missing teeth cosmetic dentistry csf leaks dental dental anesthetics dental restorations dental teeth dento alveolar fractures disease
Febrile neutropenia by DR saqib ahmad shah PG radiation oncology SKIMS KASHMIRDR Saqib Shah
This document discusses granulopoiesis, neutrophils, and neutropenia. It defines neutropenia as an abnormally low level of neutrophils in the bloodstream. Severe neutropenia, when neutrophil counts drop below 500 cells/mm3, can lead to life-threatening infections. The document outlines risk factors for infections in neutropenic cancer patients and describes the evaluation and treatment of febrile neutropenia, including assessing patient risk level to determine treatment approach.
Las infusiones prolongadas de antibióticos beta-lactámicos pueden mejorar los resultados microbiológicos y clínicos al maximizar la duración de la exposición del fármaco sobre la concentración inhibitoria mínima del patógeno. Las estrategias de infusión prolongada, como la infusión continua o prolongada de más de 3-4 horas, ayudan a alcanzar los objetivos farmacodinámicos mejor que las infusiones cortas tradicionales de 30-60 minutos. Aunque se necesitan más estudios controlados aleatorios, la evid
This document provides information on neutropenia, febrile neutropenia, prevention and treatment. It discusses definitions of neutropenia and febrile neutropenia. It outlines increased infection risk and complications of febrile neutropenia like prolonged hospitalization and increased costs. It recommends prevention measures including growth factors and antibiotics. It provides treatment guidelines for febrile neutropenia focusing on empirical antibiotic therapy based on infection site and risk factors. It discusses antifungal, antiviral and additional site-specific treatment considerations.
Preventive and therapeutic strategies in critically ill patients with highly...Sergio Paul Silva Marin
This document discusses preventive and therapeutic strategies for critically ill patients infected with highly resistant bacteria. It notes that antibiotic resistance is a major global problem, with multidrug-resistant and pandrug-resistant organisms increasingly encountered in healthcare settings. The review focuses on strategies for severely ill ICU patients, who are at high risk of nosocomial infections due to medical advances enabling longer stays. Timely diagnosis and optimized antibiotic treatment are important for managing such infections.
Neumonía Intrahospitalaria y asociada a ventilacion mecánicaInri Itzel
Definición, factores de riesgo, mecanismos de infección, microorganismos frecuentes asociados a NAVM, diagnóstico clinico en pacientes entre 1 y 12 años, diagnostico microbiologico, diagnostico radiologico, criterios para considerar una neumonia definitiva o probable, diagnostico diferencial, tratamiento y medidas preventivas.
This document discusses neutropenia and febrile neutropenia in children. It defines neutropenia as a decrease in absolute neutrophil count and describes different levels of severity from mild to profound. It outlines common causes of infection in febrile neutropenic children including bacteria, fungi, and viruses. Risk factors for serious infection are described. Guidelines are provided for evaluation, treatment including antibiotic and antifungal selection, and risk stratification of febrile neutropenic children.
Werfen Group es una corporación internacional de productos médicos de capital privado español formada por tres unidades de negocio: diagnóstico in vitro, dispositivos médicos para hospitales e instrumentos científicos. La compañía opera a nivel global a través de múltiples empresas y tiene presencia directa en 25 países y a través de distribuidores en 62 países.
abscess advanced trauma life support anterio advanced trauma life support antibiotics apically repositioned flap dental diseases dr dr shabeel drshabeel’s face eye trauma lidocaine anodontia management medical medicine misuse and abuse orthodontics teeth braces pharmacy pn preparation dental students for community based ed presentations s abscess abscess tooth active orthodonti shabeel shabeel"s shabeel’s shabeelpn trends of antimicrobial usage in dental practice View all
’s abscess abscess advanced trauma life support anterio abscess tooth active orthodontics adolescent advanced trauma life support aesthetic dentistry airway management alignment of teeth amalgam anesthesia in dentistry anesthetics in dentistry anterior open bite antibiotic resistanace antibiotics antibiotics and leukopenia aphthous ulcers apically repositioned flap apicoectomy appliances arch dental arch form orthodontics braces arch length orthodontics braces arch wire orthodontist braces ayurvedha baby teeth bloger boil books braces braces teeth cancer canker sore pain cavity preparation children community based learning congenitally missing teeth cosmetic dentistry csf leaks dental dental anesthetics dental restorations dental teeth dento alveolar fractures disease
Febrile neutropenia by DR saqib ahmad shah PG radiation oncology SKIMS KASHMIRDR Saqib Shah
This document discusses granulopoiesis, neutrophils, and neutropenia. It defines neutropenia as an abnormally low level of neutrophils in the bloodstream. Severe neutropenia, when neutrophil counts drop below 500 cells/mm3, can lead to life-threatening infections. The document outlines risk factors for infections in neutropenic cancer patients and describes the evaluation and treatment of febrile neutropenia, including assessing patient risk level to determine treatment approach.
Las infusiones prolongadas de antibióticos beta-lactámicos pueden mejorar los resultados microbiológicos y clínicos al maximizar la duración de la exposición del fármaco sobre la concentración inhibitoria mínima del patógeno. Las estrategias de infusión prolongada, como la infusión continua o prolongada de más de 3-4 horas, ayudan a alcanzar los objetivos farmacodinámicos mejor que las infusiones cortas tradicionales de 30-60 minutos. Aunque se necesitan más estudios controlados aleatorios, la evid
This document provides information on neutropenia, febrile neutropenia, prevention and treatment. It discusses definitions of neutropenia and febrile neutropenia. It outlines increased infection risk and complications of febrile neutropenia like prolonged hospitalization and increased costs. It recommends prevention measures including growth factors and antibiotics. It provides treatment guidelines for febrile neutropenia focusing on empirical antibiotic therapy based on infection site and risk factors. It discusses antifungal, antiviral and additional site-specific treatment considerations.
Preventive and therapeutic strategies in critically ill patients with highly...Sergio Paul Silva Marin
This document discusses preventive and therapeutic strategies for critically ill patients infected with highly resistant bacteria. It notes that antibiotic resistance is a major global problem, with multidrug-resistant and pandrug-resistant organisms increasingly encountered in healthcare settings. The review focuses on strategies for severely ill ICU patients, who are at high risk of nosocomial infections due to medical advances enabling longer stays. Timely diagnosis and optimized antibiotic treatment are important for managing such infections.
Neumonía Intrahospitalaria y asociada a ventilacion mecánicaInri Itzel
Definición, factores de riesgo, mecanismos de infección, microorganismos frecuentes asociados a NAVM, diagnóstico clinico en pacientes entre 1 y 12 años, diagnostico microbiologico, diagnostico radiologico, criterios para considerar una neumonia definitiva o probable, diagnostico diferencial, tratamiento y medidas preventivas.
This document discusses neutropenia and febrile neutropenia in children. It defines neutropenia as a decrease in absolute neutrophil count and describes different levels of severity from mild to profound. It outlines common causes of infection in febrile neutropenic children including bacteria, fungi, and viruses. Risk factors for serious infection are described. Guidelines are provided for evaluation, treatment including antibiotic and antifungal selection, and risk stratification of febrile neutropenic children.
This document discusses the history and classification of antimicrobials and antibiotics. It describes their discovery from mouldy curd and various plant and mineral sources. Antimicrobials are classified based on their chemical structure, mechanism of action, spectrum of activity, and source. The mechanisms of action include inhibiting cell wall synthesis, disrupting cell membranes, and interfering with protein synthesis and DNA. Issues like drug resistance, cross-resistance, superinfections, and toxicity are also covered.
This document provides an overview and guidelines for choosing antibiotics. It discusses collecting cultures before starting antibiotics and ensuring appropriate dosing. Common antibiotics are reviewed including beta-lactams like penicillins, cephalosporins, and carbapenems as well as quinolones, macrolides, and metronidazole. Factors to consider for antibiotic selection include location and type of infection, patient history, and risk of drug-resistant pathogens. Quick guides are provided for coverage of pseudomonas, anaerobes, MRSA, and VRE.
Empiric antibiotic management for major infectionsderosaMSKCC
This document provides guidance from an infectious diseases physician on various infectious disease topics. It addresses appropriate workups, empiric antibiotic choices, and treatment durations for common infections seen at MSKCC including bloodstream infections, pneumonia, intra-abdominal infections, C. difficile colitis, skin and soft tissue infections, and febrile neutropenia. Emphasis is placed on obtaining appropriate cultures prior to antibiotics and tailoring treatment based on culture results and patient risk factors.
Inappropriate Prescribing Of AntimicrobialsMmorshed217
This document discusses inappropriate combinations of antimicrobial agents. It begins by listing common resistant nosocomial pathogens such as Staphylococcus aureus and Pseudomonas aeruginosa. It then examines different classes of antimicrobials and why certain combinations should be avoided. These include combining two beta-lactams which results in therapeutic duplication, or combining a beta-lactam with a carbapenem which can have an antagonistic effect. Other inappropriate combinations discussed are fluoroquinolones with macrolides due to additive QT prolongation effects, and dual anti-anaerobic coverage with metronidazole and clindamycin. The document provides alternatives and references several clinical trials.
Part 2 - Aminoglycoside Vancomycin dosingJeff Tollison
This document provides guidance on dosing aminoglycosides and vancomycin. It discusses obtaining relevant patient information for dosing calculations including weight, height, creatinine, and infection details. It recommends using online calculators or nomograms to determine initial doses, with monitoring levels to adjust subsequent doses. For patients without labs, it suggests conservative initial loading doses until labs are available. Close monitoring is advised for elderly or renally impaired patients.
This document discusses antibiotic dosing during renal failure. It explains the importance of dose adjustments with renal impairment due to decreased drug elimination. It compares methods to calculate glomerular filtration rate (GFR) and creatinine clearance, such as the Modification of Diet in Renal Disease (MDRD) and Cockroft-Gault equations. It also describes different types of dialysis and considerations for dosing antibiotics in patients receiving dialysis or continuous renal replacement therapy.
This document discusses recent advances in the management of febrile neutropenia. It defines febrile neutropenia and outlines risk assessment scores. It recommends inpatient empirical antibiotic therapy for high-risk patients. It discusses appropriate diagnostic tests, empiric antibiotic and antifungal therapy, therapy duration, and prophylaxis. It also covers catheter-related infections, environmental precautions, and common bacterial pathogens in neutropenic patients.
The document discusses beta lactam antibiotics, focusing on penicillins. It describes how penicillin was discovered by Alexander Fleming and its mechanism of inhibiting cell wall synthesis. Penicillins are classified into natural and semisynthetic types, with natural penicillins having a narrower spectrum mainly against gram-positive cocci. Semisynthetic penicillins like ampicillin and amoxicillin have a broader spectrum. Beta lactamase inhibitors are also discussed which are often combined with penicillins to overcome bacterial resistance.
Este documento proporciona recomendaciones sobre la formulación de antibióticos para el tratamiento empírico y dirigido de diferentes infecciones, incluyendo infecciones del tracto respiratorio, abdomen, piel y otras partes del cuerpo. Incluye factores de riesgo para infecciones resistentes a los antimicrobianos y recomendaciones específicas sobre el antibiótico, dosis y duración del tratamiento según el sitio anatómico y microorganismo involucrado.
This document summarizes various types of antimicrobials including their classification based on chemical structure and mechanism of action. It describes how antimicrobials work by inhibiting processes like cell wall synthesis or protein synthesis. It also discusses problems that can arise with antimicrobial use like toxicity, hypersensitivity reactions, drug resistance through mutation or gene transfer, and superinfections. Antimicrobials are obtained from fungi, bacteria, and actinomycetes.
Neutropenia is defined as an abnormally low absolute neutrophil count (ANC) below 1,500/uL. It can be caused by infection, drugs, chemotherapy, radiation, autoimmune disorders, or genetic conditions. Common symptoms include oral infections and skin infections. Treatment depends on the severity and cause of the neutropenia but may include antibiotics, growth factors, treating the underlying cause, or supportive care. Febrile neutropenia requires prompt treatment with IV antibiotics and hospitalization for high-risk patients.
Beta lactam antibiotics include penicillins and cephalosporins. Penicillin G is a commonly used penicillin that treats streptococcal infections with doses of 0.5-5 million units given intramuscularly or intravenously for 7-10 days.
La penicilina es un antibiótico descubierto en 1928 por Alexander Fleming que mata bacterias e impide su crecimiento. Existen diferentes tipos de penicilinas como la penicilina G, F, K y X. La penicilina G es la más importante y se combina con sodio, potasio o calcio para su administración. Las penicilinas se clasifican en naturales y semisintéticas, y algunas como la penicilina V pueden administrarse por vía oral. En caso de alergia a la penicilina, se realizan pruebas cut
This document provides guidelines from the Infectious Diseases Society of America (IDSA) for the use of antimicrobial agents in managing patients with cancer who experience chemotherapy-induced fever and neutropenia. Some key points:
1. All patients who present with fever and neutropenia should receive immediate empirical antibiotic therapy with broad-spectrum antibiotics to treat both gram-positive and gram-negative pathogens.
2. Patients should be assessed for risk of complications, with high-risk patients requiring hospitalization and intravenous antibiotics. Low-risk patients may be candidates for oral outpatient therapy.
3. Initial testing should include blood cultures and tests to assess organ function, with additional cultures as clinically indicated. Chest imaging
This document discusses antibiotics, including their definition, classification, mechanisms of action, and advantages and disadvantages. It provides information on common synthetic antibiotics such as penicillin, cephalosporin, chloramphenicol, and others. The document outlines how antibiotics are classified based on their mechanism of action, spectrum of activity, and mode of action. It also notes some potential side effects of antibiotics and issues that can arise from their improper use.
This document provides technical information about various industrial robot models from HIWIN. It includes specifications for the KK, SK, KA, KS, KU, and KE series robots. It discusses features, applications, system components, selection steps, precision, speed, and other characteristics. The document is intended to help customers choose the appropriate robot for their needs.
Os mostramos las claves de un buen plan de comunicación: análisis y planificación, acotar objetivos, identifica tu público objetivo, desarrollar las acciones, definir el mensaje, identificar los canales, la programación y la medición de resultados.
This report looks at the prospects for economic integration between Ukraine and the European Union. The so-called Orange Revolution of late 2004 saw the question of Ukraine’s future geopolitical orientation re-emerge, and the idea of closer integration with the EU received wide social support. Yet, already by mid-2006 the political support to the idea of Euro-Atlantic integration seem to diminish. It is not clear if, how and when the idea of deeper integration with the EU will be put into action.
Although the main steps have been charted at the official level (Ukraine becoming WTO member and both sides start to gradually lower barriers to trade in manufacturing goods), neither their timing, nor the steps going beyond them can be specified with any degree of certainty. This report aims at showing the possible and optimal policy options.
Authored by:
Authored by: Dmytro Boyarchuk, Inna Golodniuk, Malgorzata Jakubiak, Anna Kolesnichenko, Mykyta Mykhaylychenko, Wojciech Paczynski, Anna Tsarenko, Vitaly Vavryschuk
Published in 2006
This document discusses the history and classification of antimicrobials and antibiotics. It describes their discovery from mouldy curd and various plant and mineral sources. Antimicrobials are classified based on their chemical structure, mechanism of action, spectrum of activity, and source. The mechanisms of action include inhibiting cell wall synthesis, disrupting cell membranes, and interfering with protein synthesis and DNA. Issues like drug resistance, cross-resistance, superinfections, and toxicity are also covered.
This document provides an overview and guidelines for choosing antibiotics. It discusses collecting cultures before starting antibiotics and ensuring appropriate dosing. Common antibiotics are reviewed including beta-lactams like penicillins, cephalosporins, and carbapenems as well as quinolones, macrolides, and metronidazole. Factors to consider for antibiotic selection include location and type of infection, patient history, and risk of drug-resistant pathogens. Quick guides are provided for coverage of pseudomonas, anaerobes, MRSA, and VRE.
Empiric antibiotic management for major infectionsderosaMSKCC
This document provides guidance from an infectious diseases physician on various infectious disease topics. It addresses appropriate workups, empiric antibiotic choices, and treatment durations for common infections seen at MSKCC including bloodstream infections, pneumonia, intra-abdominal infections, C. difficile colitis, skin and soft tissue infections, and febrile neutropenia. Emphasis is placed on obtaining appropriate cultures prior to antibiotics and tailoring treatment based on culture results and patient risk factors.
Inappropriate Prescribing Of AntimicrobialsMmorshed217
This document discusses inappropriate combinations of antimicrobial agents. It begins by listing common resistant nosocomial pathogens such as Staphylococcus aureus and Pseudomonas aeruginosa. It then examines different classes of antimicrobials and why certain combinations should be avoided. These include combining two beta-lactams which results in therapeutic duplication, or combining a beta-lactam with a carbapenem which can have an antagonistic effect. Other inappropriate combinations discussed are fluoroquinolones with macrolides due to additive QT prolongation effects, and dual anti-anaerobic coverage with metronidazole and clindamycin. The document provides alternatives and references several clinical trials.
Part 2 - Aminoglycoside Vancomycin dosingJeff Tollison
This document provides guidance on dosing aminoglycosides and vancomycin. It discusses obtaining relevant patient information for dosing calculations including weight, height, creatinine, and infection details. It recommends using online calculators or nomograms to determine initial doses, with monitoring levels to adjust subsequent doses. For patients without labs, it suggests conservative initial loading doses until labs are available. Close monitoring is advised for elderly or renally impaired patients.
This document discusses antibiotic dosing during renal failure. It explains the importance of dose adjustments with renal impairment due to decreased drug elimination. It compares methods to calculate glomerular filtration rate (GFR) and creatinine clearance, such as the Modification of Diet in Renal Disease (MDRD) and Cockroft-Gault equations. It also describes different types of dialysis and considerations for dosing antibiotics in patients receiving dialysis or continuous renal replacement therapy.
This document discusses recent advances in the management of febrile neutropenia. It defines febrile neutropenia and outlines risk assessment scores. It recommends inpatient empirical antibiotic therapy for high-risk patients. It discusses appropriate diagnostic tests, empiric antibiotic and antifungal therapy, therapy duration, and prophylaxis. It also covers catheter-related infections, environmental precautions, and common bacterial pathogens in neutropenic patients.
The document discusses beta lactam antibiotics, focusing on penicillins. It describes how penicillin was discovered by Alexander Fleming and its mechanism of inhibiting cell wall synthesis. Penicillins are classified into natural and semisynthetic types, with natural penicillins having a narrower spectrum mainly against gram-positive cocci. Semisynthetic penicillins like ampicillin and amoxicillin have a broader spectrum. Beta lactamase inhibitors are also discussed which are often combined with penicillins to overcome bacterial resistance.
Este documento proporciona recomendaciones sobre la formulación de antibióticos para el tratamiento empírico y dirigido de diferentes infecciones, incluyendo infecciones del tracto respiratorio, abdomen, piel y otras partes del cuerpo. Incluye factores de riesgo para infecciones resistentes a los antimicrobianos y recomendaciones específicas sobre el antibiótico, dosis y duración del tratamiento según el sitio anatómico y microorganismo involucrado.
This document summarizes various types of antimicrobials including their classification based on chemical structure and mechanism of action. It describes how antimicrobials work by inhibiting processes like cell wall synthesis or protein synthesis. It also discusses problems that can arise with antimicrobial use like toxicity, hypersensitivity reactions, drug resistance through mutation or gene transfer, and superinfections. Antimicrobials are obtained from fungi, bacteria, and actinomycetes.
Neutropenia is defined as an abnormally low absolute neutrophil count (ANC) below 1,500/uL. It can be caused by infection, drugs, chemotherapy, radiation, autoimmune disorders, or genetic conditions. Common symptoms include oral infections and skin infections. Treatment depends on the severity and cause of the neutropenia but may include antibiotics, growth factors, treating the underlying cause, or supportive care. Febrile neutropenia requires prompt treatment with IV antibiotics and hospitalization for high-risk patients.
Beta lactam antibiotics include penicillins and cephalosporins. Penicillin G is a commonly used penicillin that treats streptococcal infections with doses of 0.5-5 million units given intramuscularly or intravenously for 7-10 days.
La penicilina es un antibiótico descubierto en 1928 por Alexander Fleming que mata bacterias e impide su crecimiento. Existen diferentes tipos de penicilinas como la penicilina G, F, K y X. La penicilina G es la más importante y se combina con sodio, potasio o calcio para su administración. Las penicilinas se clasifican en naturales y semisintéticas, y algunas como la penicilina V pueden administrarse por vía oral. En caso de alergia a la penicilina, se realizan pruebas cut
This document provides guidelines from the Infectious Diseases Society of America (IDSA) for the use of antimicrobial agents in managing patients with cancer who experience chemotherapy-induced fever and neutropenia. Some key points:
1. All patients who present with fever and neutropenia should receive immediate empirical antibiotic therapy with broad-spectrum antibiotics to treat both gram-positive and gram-negative pathogens.
2. Patients should be assessed for risk of complications, with high-risk patients requiring hospitalization and intravenous antibiotics. Low-risk patients may be candidates for oral outpatient therapy.
3. Initial testing should include blood cultures and tests to assess organ function, with additional cultures as clinically indicated. Chest imaging
This document discusses antibiotics, including their definition, classification, mechanisms of action, and advantages and disadvantages. It provides information on common synthetic antibiotics such as penicillin, cephalosporin, chloramphenicol, and others. The document outlines how antibiotics are classified based on their mechanism of action, spectrum of activity, and mode of action. It also notes some potential side effects of antibiotics and issues that can arise from their improper use.
This document provides technical information about various industrial robot models from HIWIN. It includes specifications for the KK, SK, KA, KS, KU, and KE series robots. It discusses features, applications, system components, selection steps, precision, speed, and other characteristics. The document is intended to help customers choose the appropriate robot for their needs.
Os mostramos las claves de un buen plan de comunicación: análisis y planificación, acotar objetivos, identifica tu público objetivo, desarrollar las acciones, definir el mensaje, identificar los canales, la programación y la medición de resultados.
This report looks at the prospects for economic integration between Ukraine and the European Union. The so-called Orange Revolution of late 2004 saw the question of Ukraine’s future geopolitical orientation re-emerge, and the idea of closer integration with the EU received wide social support. Yet, already by mid-2006 the political support to the idea of Euro-Atlantic integration seem to diminish. It is not clear if, how and when the idea of deeper integration with the EU will be put into action.
Although the main steps have been charted at the official level (Ukraine becoming WTO member and both sides start to gradually lower barriers to trade in manufacturing goods), neither their timing, nor the steps going beyond them can be specified with any degree of certainty. This report aims at showing the possible and optimal policy options.
Authored by:
Authored by: Dmytro Boyarchuk, Inna Golodniuk, Malgorzata Jakubiak, Anna Kolesnichenko, Mykyta Mykhaylychenko, Wojciech Paczynski, Anna Tsarenko, Vitaly Vavryschuk
Published in 2006
CASE Network Report 66 - Prospects for EU-Ukraine Economic Relations
Alopáticos2011
1. COMISIÓN DE AUTORIZACIÓN SANITARIA
DIRECCIÓN EJECUTIVA DE AUTORIZACIÓN DE PRODUCTOS Y ESTABLECIMIENTOS
RELACIÓN DE REGISTROS DE MEDICAMENTOS ALOPÁTICOS EXPEDIDOS DURANTE EL AÑO DE 2011
Denominación distintiva Denominación genérica Forma farmacéutica
Clasificación
Artículo 226
LGS
Titular Vencimiento Clasificación
Registro
sanitario / SSA
VICLOVIR Aciclovir Crema VI Laboratorios Kener, S.A. de C.V. 11-abr-2016 MG 062M2011
AVIREX-I Aciclovir Solución IV Tecnofarma, S.A. de C.V. 6-ene-2017 MG 194M2011
ALKA-SELTZER BOOST Ácido acetilsalicílico / cafeína Tableta VI Bayer de México, S.A. de C.V. 24-ago-2016 MG 206M2011
DUOCOVER Ácido acetilsalicílico / clopidogrel Tableta IV
Bristol Myers Squibb de México, S. de R.L. de
C.V.
27-ene-2016 MN 019M2011
SINCRONIUM
Ácido acetilsalicílico / simvastatina /
ramipril
Cápsula IV Laboratorios Bioserum México, S.A. de C.V. 7-dic-2016 MN 289M2011
SERCASER
Ácido acetilsalicíñico / ácido citrico /
bicarbonato de sodio
Tableta VI Serral, S.A. de C.V. 13-ene-2016 MG 012M2011
ZEROCLAST Ácido alendrónico Tableta IV Innovare R & D, S.A. de C.V. 2-feb-2016 MG 024M2011
ACCOCEPT Ácido micofenólico Tableta IV Innovare R & D, S.A. de C.V. 14-mar-2016 MG 045M2011
T-RUXICO Ácido ursodeoxicólico Cápsula IV Ultra Laboratorios, S.A. de C.V. 14-ene-2016 MG 013M2011
UDCA FERRING Ácido ursodeoxicólico Cápsula IV Ferring, S.A. de C.V. 1-ago-2016 MG 188M2011
ZENDYX Albendazol / quinfanida Suspensión VI Laboratorios Columbia, S.A. de C.V. 1-ago-2016 MG 175M2011
FRESHCLEAR Alcohol polivinílico / fenilefrina Solución ´VI Allergan, S.A. de C.V. 14-mar-2016 MN 041M2011
ULTRACRIS Alprazolam Tableta II Ultra Laboratorios, S.A. de C.V. 27-ene-2016 MG 022M2011
PROSTAVASIN Alprostadil Solución IV Productos Farmacéuticos, S.A. de C.V. 29-mar-2016 MG 057M2011
LETREVIR Amantadina Tableta IV Laboratorios Alpharma, S.A. de C.V. 1-ago-2016 MG 177M2011
GRISTALIT Ambroxol / loratadina Solución VI Biomep, S.A. de C.V. 3-nov-2016 MG 212M2011
ANFAKAIR Amfotericina B Solución ÍV Alvartis Pharma, S.A. de C.V. 29-abr-2016 MG 069M2011
ESLODINEPIN Amlodipino Tableta IV Armstrong Laboratorios de México, S.A. de C.V. 7-ene-2016 MG 005M2011
AMBEL-TEC Amlodipino Tableta IV Tecnofarma, S.A. de C.V. 6-ene-2017 MG 182M2011
APROVASC Amlodipino / irbesartán Tableta IV Sanofi - Aventis de México, S.A. de C.V. 13-jul-2016 MN 180M2011
PROBITOR Anastrozol Tableta IV Innovare R & D, S.A. de C.V. 25-ene-2016 MG 018M2011
ZUROZOL Anastrozol Tableta IV Zurich Pharma, S.A. de C.V. 3-ago-2016 MG 196M2011
ASOINACOR Anastrozol Tableta IV Asofarma de México, S.A. de C.V. 1-ago-2016 MG 200M2011
BLODVIT Atorvastatina Tableta IV Sandoz, S.A. de C.V. 31-ene-2016 MG 020M2011
APOLISTINA Atorvastatina Tableta IV Protein, S.A. de C.V. 5-oct-2016 MG 221M2011
INASTOR Atorvastatina Tableta IV Lemery, S.A. de C.V. 5-oct-2016 MG 223M2011
THOREVA Atorvastatina Tableta IV Laboratorios Liomont, S.A. de C.V. 5-oct-2016 MG 224M2011
AREVA Atorvastatina Tableta IV Pharmagen, S.A. de C.V. 5-oct-2016 MG 225M2011
Página 1 de 8 Diciembre 2011
2. Denominación distintiva Denominación genérica Forma farmacéutica
Clasificación
Artículo 226
LGS
Titular Vencimiento Clasificación
Registro
sanitario / SSA
INMETCOL Atorvastatina Tableta IV Psicofarma, S.A. de C.V. 10-nov-2016 MG 277M2011
EDARBI Azilsartán medoxomilo Tableta IV Takeda Pharmaceutical Company Limited 30-may-2016 MN 106M2011
INNOVAIR Bclometasona / formoterol Aerosol IV Emifarma, S.A. de C.V. 13-dic-2016 MR 295M2011
HEPORAX Bemiparina de sodio Solución IV Laboratorios Pisa, S.A. de C.V. 29-abr-2016 MG 070M2011
ORTOBEX Bencidamina Solución VI Serral, S.A. de C.V. 13-ene-2016 MG 011M2011
BENSITRAK Besilato de cisatracurio Solución IV Laboratorios Pisa, S.A. de C.V. 16-dic-2016 MG 317M2011
KRAFASIN Betametasona / clotrimazol / gentamicina Crema IV Dankel Medical, S.A. de C.V. 1-mar-2016 MG 032M2011
GINATRIFIL Betametasona / clotrimazol / gentamicina Crema IV Laboratorios Best, S.A. 28-feb-2016 MG 039M2011
ZUPROT Bicalutamida Tableta IV Zurich Pharma, S.A. de C.V. 8-nov-2016 MG 254M2011
APOTECTOR Bicalutamida Tableta IV Protein, S.A. de C.V. 8-nov-2016 MG 269M2011
VICTRELIS Boceprevir Cápsula IV Merck Sharp & Dohme, S.A. de C.V. 18-nov-2016 MN 285M2011
DALVEAR Bromhexina / dropropizina Jarabe IV Laboratorios Columbia, S.A. de C.V. 14-sep-2016 MN 211M2011
ZELLAX Bromuro de vecuronio Solución IV Innovare R & D, S.A. de C.V. 11-feb-2016 MG 030M2011
HERBANE Buprenorfina Solución II Psicofarma, S.A. de C.V. 16-dic-2016 MG 330M2011
BUTREW SBK Bupropion Tableta IV
Laboratorio Médico Químico Biológico, S.A. de
C.V.
26-ene-2017 MG 133M2011
ZAAT Cafeína Tableta VI Genomma Laboratories México, S.A. de C.V. 23-feb-2016 MG 037M2011
BAXYPIME Cefepima Solución IV Laboratorios Zerboni, S.A. 15-mar-2016 MG 047M2011
XENTRIAC I.V. Ceftriaxona Solución IV Productos Maver, S.A. de C.V. 7-jul-2016 MG 160M2011
ESMISEN
Cianocobalamina / ketorolaco / piridoxina
/ tiamina
Solución IV Laboratorios Senisiain, S.A. de C.V. 3-nov-2016 MG 217M2011
ESMISEN
Cianocobalamina / ketorolaco / piridoxina
/ tiamina
Tableta IV Laboratorios Senisiain, S.A. de C.V. 6-ene-2016 MG 002M2011
MIMPARA Cinacalcet Tableta IV Amgen Inc 15-nov-2016 MN 213M2011
BACTRICIP Ciprofloxacino Solución IV Laboratorios Keton de México, S.A. de C.V. 6-ene-2017 MG 204M2011
SOPHIXIN DX UNGENA Ciprofloxacino / dexametasona Ungüento IV Laboratorios Sophia, S.A. de C.V. 14-dic-2016 MG 275M2011
ZUPHACIT Citarabina Solución IV Zurich Pharma, S.A. de C.V. 11-may-2016 MG 082M2011
BACOFF Clindamicina Solución IV Tecnofarma, S.A. de C.V. 29-abr-2016 MG 074M2011
MAVIFEM Clindamicina / ketoconazol Crema IV Mavi Farmacéutica, S.A. de C.V. 22-sep-2016 MG 222M2011
TOPIFORT Clobetasol Crema IV Productos Científicos, S.A. de C.V. 9-mar-2016 MG 035M2011
SISTEMA GB Clobetasol / minoxidil / tretinoina Solución VI Laboratorios Valdecasas, S.A. 16-dic-2016 MN 325M2011
RETROZAN Clonazepam Tableta II Ultra Laboratorios, S.A. de C.V. 27-ene-2016 MG 021M2011
DEGREGAN Clopidogrel Tableta IV Laboratorios Liomont, S.A. de C.V. 15-dic-2016 MG 301M2011
AGGRELES Clopidogrel Tableta IV Ultra Laboratorios, S.A. de C.V. 16-dic-2016 MG 303M2011
DOPICLOL Clopidogrel Tableta IV Nafar Laboratorios, S.A. de C.V. 15-dic-2016 MG 305M2011
NABRATIN Clopidogrel Tableta IV Asofarma de México, S.A. de C.V. 16-dic-2016 MG 308M2011
Página 2 de 8 Diciembre 2011
3. Denominación distintiva Denominación genérica Forma farmacéutica
Clasificación
Artículo 226
LGS
Titular Vencimiento Clasificación
Registro
sanitario / SSA
CERCLODEL Clopidogrel Tableta IV Laboratorios Vanquish, S.A. de C.V. 16-dic-2016 MG 309M2011
FABIPLAC Clopidogrel Tableta IV Laboratorios Farmadem, S.A. de C.V. 16-dic-2016 MG 311M2011
DEVIPLAT Clopidogrel Tableta IV Novag Infancia, S.A. de C.V. 15-dic-2016 MG 313M2016
OLFOVEL Clopidogrel Tableta IV Sandoz, S.A. de C.V. 16-dic-2016 MG 314M2011
FLUCOGREL Clopidogrel Tableta IV Laboratorios Senisiain, S.A. de C.V. 16-dic-2016 MG 316M2011
HEXYR Clopidogrel Tableta IV Emifarma, S.A. de C.V. 16-dic-2016 MG 318M2011
DOGRENAP Clopidogrel Tableta IV Grupo Medifarma, S.A. de C.V. 16-dic-2016 MG 324M2011
PLAVANCE Clopidogrel Tableta IV Laboratorios Kendrick, S.A. 16-dic-2016 MG 326M2011
RANPIDO Clopidogrel Tableta IV Laboratorios Zerboni, S.A. 16-dic-2016 MG 332M2011
EQOSMOT Cloruro de potasio Solución IV Laboratorios Alpharma, S.A. de C.V. 16-feb-2016 MG 027M2011
VERACARE Cloruro de sodio Solución IV Fresenius Medical Care de México, S.A. de C.V. 11-jul-2016 MG 162M2011
LOZAMIR-C Clotrimazol Crema VI Biomep, S.A. de C.V. 12-abr-2016 MG 063M2011
LOMECAN V Clotrimazol Óvulo VI Genomma Laboratories México, S.A. de C.V. 1-mar-2016 MG 038M2011
ARANESP Darbopoetina alfa Solución IV Amgen, Inc. 18-abr-2016 MT 066M2011
TOVADART Deflazacort Tableta IV Ultra Laboratorios, S.A. de C.V. 1-ago-2016 MG 198M2011
PROLIA Denosumab Solución IV Amgen, Inc. 18-abr-2016 MT 067M2011
DESLIBAL Desloratadina Tableta IV Sandoz, S.A. de C.V. 28-mar-2016 MG 054M2011
AVIANT REDITABS Desloratadina Tableta IV Schering-Plough, S.A. de C.V. 10-nov-2017 MG 281M2011
AZOMIR REDI TABS Desloratadina Tableta IV Undra, S.A. de C.V. 21-dic-2016 MG 284M2011
VIEPRYS Desonida Crema IV Laboratorios Dermatológicos Darier, S.A. de C.V. 18-mar-2016 MG 052M2011
VIEPRYS HIDROGEL Desonida Gel IV Laboratorios Dermatológicos Darier, S.A. de C.V. 8-jul-2016 MG 165M2011
DEXIVANT Dexlansoprazol Cápsula IV Takeda Pharmaceutical Company Limited 20-abr-2016 MN 068M2011
OACEREIN Diacereína Cápsula IV Laboratorios Keton de México, S.A. de C.V. 2-ago-2016 MG 191M2011
DIMICIN Dicloxacilina Solución IV
Industrias Químico Farmacéuticas Americanas,
S.A. de C.V.
17-nov-2016 MG 286M2011
DIMENSAL Difenidol Solución IV Laboratorios Alpharma, S.A. de C.V. 6-ene-2016 MG 004M2011
ASODOC Docetaxel Solución IV Asofarma de México, S.A. de C.V. 15-dic-2016 MG 297M2011
TAXULIDE Docetaxel Solución IV Laboratorios Cryopharma, S.A. de C.V. 15-dic-2016 MG 302M2011
SOULAXCIN Docetaxel Solución IV Laboratorios Pisa, S.A. de C.V. 15-dic-2016 MG 307M2011
ARACET Docetaxel Solución IV Mavi Farmacéutica, S.A. de C.V. 15-dic-2016 MG 310M2011
PROSAGLIC Docetaxel Solución IV Sandoz, S.A. de C.V. 15-dic-2016 MG 312M2011
DOCILVAN Docetaxel Solución IV Laboratorios Vanquish, S.A. de C.V. 16-dic-2016 MG 319M2011
BRESTABINA Docetaxel Solución IV Dinafarma, S.A. de C.V. 16-dic-2016 MG 320M2011
TEVAXTER Docetaxel Solución IV Lemery, S.A. de C.V. 16-dic-2016 MG 321M2011
TAXANIT Docetaxel Solución IV Intas Pharmaceuticals Ltd. 16-dic-2016 MG 323M2011
Página 3 de 8 Diciembre 2011
4. Denominación distintiva Denominación genérica Forma farmacéutica
Clasificación
Artículo 226
LGS
Titular Vencimiento Clasificación
Registro
sanitario / SSA
DODETAX Docetaxel Solución IV Probiomed, S.A. de C.V. 16-dic-2016 MG 328M2011
DIGISOS Domperidona Tableta IV Productos Medix, S.A de C.V. 6-jul-2016 MG 158M2011
HECTOROL Doxercalciferol Cápsula IV Productos Farmacéuticos, S.A. de C.V. 29-ago-2016 MN 192M2011
DHARMA Duloxetina Cápsula IV Farmacéuticos Rayere, S.A. 22-mar-2016 MG 053M2011
TREDALITOS Electrolitos orales Polvo VI Grimann, S.A. de C.V. 29-mar-2016 MG 050M2011
HYSEPIK Epinestina Tableta VI Ultra Laboratorios, S.A. de C.V. 6-ene-2017 MG 239M2011
QLAIRA Estradiol / dienogest Comprimido IV Bayer de México, S.A. de C.V. 18-mar-2016 MG 049M2011
REPTOQUIN Estreptoquinasa Solución IV Alvartis Pharma, S.A. de C.V. 27-ene-2016 MB 006M2011
TROMODIL-V Estrógenos conjugados Solución IV Dankel Medical, S.A. de C.V. 6-ene-2017 MG 205M2011
CRYOSID Etopósido Solución IV Laboratorios Cryopharma, S.A. de C.V. 23-nov-2016 MG 242M2011
PREMONE Etrógenos conjugados Crema IV Ultra Laboratorios, S.A. de C.V. 4-nov-2016 MG 259M2011
KEDRIFIX Factor IX Solución IV Serral, S.A. de C.V. 18-ago-2016 MB 181M2011
BRAFELIX Fenilefrina / loratadina Solución IV Degort's Chemival, S.A. de C.V. 2-ago-2016 MG 184M2011
FENSI Fenitoina Solución IV Laboratorios Solfran, S.A. 5-sep-2016 MG 214M2011
BIOSTAFEX Fexofenadina Tableta IV Biomep, S.A. de C.V. 17-feb-2016 MG 036M2011
NALUDON-K Fitomenadiona Solución IV Tecnofarma, S.A. de C.V. 2-may-2016 MG 072M2011
ACETAFLUR Fludarabina Solución ÍV Lemery, S.A. de C.V. 18-nov-2016 MG 249M2011
ZYPRED Gatifloxacino / prednisolona Suspensión IV Allergan, S.A. de C.V. 14-mar-2016 MN 046M2011
ZARBIN Gemcitabina Solución IV Dinafarma, S.A. de C.V. 9-may-2016 MG 079M2011
PAMIGEN Gemcitabina Solución IV Asofarma de México, S.A. de C.V. 6-oct-2016 MG 220M2011
BOLIGEM Gemcitabina Solución IV Lemery, S.A. de C.V. 5-oct-2016 MG 226M2011
TRIAMZAR Gemcitabina Solución IV Laboratorios Pisa, S.A. de C.V. 5-oct-2016 MG 228M2011
GEMXIT Gemcitabina Solución IV Laboratorios Cryopharma, S.A. de C.V. 5-oct-2016 MG 232M2011
LINFOGEBIN Gemcitabina Solución IV Sandoz, S.A. de C.V. 5-oct-2016 MG 233M2011
GEMPAR Gemcitabina Solución IV Stern Pharma GmbH, S.A. de C.V. 5-oct-2016 MG 234M2011
TABINEX Gemcitabina Solución IV Mavi Farmacéutica, S.A. de C.V. 5-oct-2016 MG 236M2011
CELGE Gemcitabina Solución IV Sun Pharma de México, S.A. de C.V. 10-nov-2016 MG 276M2011
TOPETENO Gemcitabina Solución IV Serral, S.A. de C.V. 10-nov-2016 MG 278M2011
LINFOGEBIN Gemcitabina Solución IV Sandoz, S.A. de C.V. 6-dic-2016 MG 296M2011
XINERID Glibenclamida / metformina Tableta IV Nycomed, S.A. de C.V. 2-feb-2016 MG 016M2011
FENOCOL Guaifenesina / oxolamina Jarabe VI Biomep, S.A. de C.V. 7-abr-2016 MG 058M2011
TICOFRAN Hidrocortisona Solución IV Laboratorios Solfran, S.A. 19-oct-2016 MG 246M2011
HIMOP Hidromorfona Solución I Psicofarma, S.A. de C.V. 18-mar-2016 MG 033M2011
PALCOL Hioscina Tableta VI Protein, S.A. de C.V. 16-feb-2016 MG 028M2011
IFADEX Ifosfamida Solución IV Laboratorios Cryopharma, S.A. de C.V. 23-nov-2016 MG 241M2011
KEYRHO Inmunoglobulina humana Anti-D Solución IV Serral, S.A. de C.V. 14-ene-2016 MB 014M2011
ZURISAR Irinotecan Solución IV Zurich Pharma, S.A. de C.V. 12-may-2016 MG 086M2011
TEXCAN Irinotecan Solución IV Stern Pharma GmbH, S.A. de C.V. 10-nov-2016 MG 282M2011
Página 4 de 8 Diciembre 2011
5. Denominación distintiva Denominación genérica Forma farmacéutica
Clasificación
Artículo 226
LGS
Titular Vencimiento Clasificación
Registro
sanitario / SSA
DARITEX-A Irinotecán Solución IV Fresenius Kabi México, S.A. de C.V. 8-dic-2016 MG 169M2011
REUMOPHAN GEL Ketoprofeno Gel VI Grisi Hnos., S.A, de C.V. 1-ago-2016 MG 178M2011
PROFENID INFANTIL Ketoprofeno Jarabe IV Sanofi - Aventis de México, S.A. de C.V. 12-abr-2016 MG 061M2011
RAPIX RD Ketorolaco Tableta IV Laboratorios Senisiain, S.A. de C.V. 1-nov-2016 MG 248M2011
FORCEDOL Ketorolaco / tramadol Cápsula IV Laboratorios Keton de México, S.A. de C.V. 11-ene-2016 MG 003M2011
FORCEDOL Ketorolaco / tramadol Solución IV Laboratorios Keton de México, S.A. de C.V. 19-may-2016 MG 087M2011
MAVIDOL TR Ketorolaco trometamina / tramadol Cápsula IV Mavi Farmacéutica, S.A. de C.V. 6-ene-2016 MG 009M2011
VIMPAT Lacosamida Solución IV Productos Farmacéuticos, S.A. de C.V. 27-ene-2016 MG 017M2011
BIOGAIA Lactobacillus reuteri protectis Tableta VI Ferring, S.A. de C.V. 8-sep-2016 MB 083M2011
TIRAPIL Levetiracetam Tableta IV Lemery, S.A. de C.V. 27-oct-2016 MG 250M2011
JADELLE Levonorgestrel Implante IV Bayer de México, S.A. de C.V. 18-mar-2016 MG 044M2011
POSTDAY LC Levonorgestrel Tableta IV Investigación Farmacéutica, S.A. de C.V. 16-feb-2016 MG 034M2011
GOODSIT Lidocaína / hidrocortisona Supositorio VI Laboratorios Química Son's, S.A. de C.V. 29-mar-2016 MG 056M2011
SENSIBIT Loratadina Tableta VI Laboratorios Liomont, S.A. de C.V. 8-sep-2016 MG 218M2011
LOZAM Lorazepam Solución II Psicofarma, S.A. de C.V. 1-ago-2016 MG 199M2011
PLIMBOX Lorazepam Tableta II Laboratorios Pisa, S.A. de C.V. 12-ene-2016 MG 008M2011
KIRRUZ L-Ornitina / L-Aspartato Granulado IV Ultra Laboratorios, S.A. de C.V. 2-feb-2016 MG 026M2011
LEVERSTAT Losartán Comprimido IV Nucitec, S.A. de C.V. 1-ago-2016 MG 187M2011
TECNOSART Losartán Tableta IV Tecnofarma, S.A. de C.V. 6-may-2016 MG 076M2011
BAXYNEM Meropenem Solución IV Laboratorios Zerboni, S.A. 6-ene-2016 MG 007M2011
DISMINONA Metilprednisolona Solución IV Dankel Medical, S.A. de C.V. 6-ene-2017 MG 171M2011
LOPITROL Metoprolol Tableta IV Química y Farmacia, S.A. de C.V. 9-mar-2016 MG 042M2011
TENAFLOX Metronidazol Solución IV Laboratorios Keton de México, S.A. de C.V. 6-ene-2017 MG 203M2011
FLAGENASE VG Metronidazol / nistatina Cápsula V Laboratorios Liomont, S.A. de C.V. 18-nov-2016 MG 288M2011
ZACAFEMYL Mifepristona Tableta III Monticello Drug Company, S.A. 9-mar-2016 MN 043M2011
METACTIV Mometasona Crema IV Laboratorios Keton de México, S.A. de C.V. 6-ene-2017 MG 215M2011
DRIMON Montelukast Comprimido IV Lemery, S.A. de C.V. 15-dic-2016 MG 293M2011
IMVLO Montelukast Granulado IV Undra, S.A. de C.V. 16-dic-2016 MG 329M2011
SANSIBAST PEDIATRICO Montelukast Tableta IV Sandoz, S.A. de C.V. 16-dic-2016 MG 290M2011
SANSIBAST Montelukast Tableta IV Sandoz, S.A. de C.V. 16-dic-2016 MG 292M2011
INHALST Montelukast Tableta IV Serral, S.A. de C.V. 16-dic-2016 MG 294M2011
EVEREST Montelukast Tableta IV Laboratorios Liomont, S.A. de C.V. 15-dic-2016 MG 298M2011
CUBRAXIS Montelukast Tableta IV Glaxosmithkline México, S.A. de C.V. 15-dic-2016 MG 299M2016
SENOVITAL Montelukast Tableta IV Laboratorios Senisiain, S.A. de C.V. 16-dic-2016 MG 300M2011
CUBRAXIS M Montelukast Tableta IV Glaxosmithkline México, S.A. de C.V. 16-dic-2016 MG 304M2011
IMVLO Montelukast Tableta IV Undra, S.A. de C.V. 15-dic-2016 MG 306M2011
IMVLO Montelukast Tableta IV Undra, S.A. de C.V. 16-dic-2016 MG 315M2006
BAXIMONT-CH Montelukast Tableta IV Ranbaxy Laboratories Limited 16-dic-2016 MG 322M2011
Página 5 de 8 Diciembre 2011
6. Denominación distintiva Denominación genérica Forma farmacéutica
Clasificación
Artículo 226
LGS
Titular Vencimiento Clasificación
Registro
sanitario / SSA
BAXIMONT Montelukast Tableta IV Ranbaxy Laboratories Limited 16-dic-2016 MG 327M2011
BIOGENFINE Morfina Solución I Psicofarma, S.A. de C.V. 20-sep-2016 MG 080M2011
MOEBIUS-G Mosaprida Suspensión IV Laboratrorios Liomont, S.A. de C.V. 2-ago-2016 MG 190M2011
IBETIDA GP Octreotida Solución IV Stern Pharma GmbH, S.A. de C.V. 1-ago-2016 MG 197M2011
COGNYX Olanzapina Tableta IV Lemery, S.A. de C.V. 8-nov-2016 MG 255M2011
OXATECH Olanzapina Tableta IV Productos Maver, S.A. de C.V. 8-nov-2016 MG 258M2011
MARCATO Olanzapina Tableta IV Protein, S.A. de C.V. 8-nov-2016 MG 260M2011
OPZYPREX Olanzapina Tableta IV Innovare R & D, S.A. de C.V. 8-nov-2016 MG 261M2011
PERFETAX Olanzapina Tableta IV Ultra Laboratorios, S.A. de C.V. 8-nov-2016 MG 264M2011
ESQUEXA Olanzapina Tableta IV Lemery, S.A. de C.V. 9-nov-2016 MG 272M2011
FINULCER Omeprazol Solución IV Industrias Suanca, S.A. de C.V. 6-ene-2017 MG 202M2011
LOZARPEM Omeprazol Solución IV Laboratorios Solfran, S.A. 19-oct-2016 MG 230M2011
EYETRON Ondansetrón Solución IV Tecnofarma, S.A. de C.V. 29-abr-2016 MG 071M2011
TRONDOX Ondansetrón Solución IV Randall Laboratories, S.A. de C.V. 1-ago-2016 MG 183M2011
SOLSET Ondansetrón Solución IV Laboratorios Solfran, S.A. 18-nov-2016 MG 283M2011
AGILEZZA Orlistat Cápsula IV Merck, S.A. de C.V. 6-may-2016 MG 077M2011
LACINEY Orlistat Cápsula IV Bruluagsa, S.A. de C.V. 26-may-2016 MG 085M2011
SUANCOX Oxaliplatino Solución IV Industrias Suanca, S.A. de C.V. 11-feb-2016 MG 025M2011
OXITAN Oxaliplatino Solución IV Fresenius Kabi México, S.A. de C.V. 8-dic-2016 MG 166M2011
ZETOXEN Oxcarbazepina Tableta IV Ultra Laboratorios, S.A. de C.V. 30-ago-2016 MG 201M2011
SINFONIL Oxcarbazepina Tableta IV Productos Maver, S.A. de C.V. 6-ene-2017 MG 235M2011
VECTIBIX Panitumumab Solución IV Amgen, Inc. 18-abr-2016 MT 065M2011
TEVIRTAL M Paracetamol Tableta VI Lemery, S.A. de C.V. 22-mar-2016 MG 048M2011
ZENTOCID Pentoxifilina Tableta IV Productos Farmacéuticos Collins, S.A. de C.V. 19-oct-2016 MG 243M2011
LEXITO Picosulfato de sodio Solución VI Laboratorios Dr. Monfort, S.A. de C.V. 2-ago-2016 MG 185M2011
DIAZATOS Pioglitazona Tableta IV Sandoz, S.A. de C.V. 5-oct-2016 MG 172M2011
RELEXIL Pioglitazona Tableta IV Lemery, S.A. de C.V. 5-oct-2016 MG 219M2011
ACCOTAZ Pioglitazona Tableta IV Innovare R & D, S.A. de C.V. 5-oct-2016 MG 227M2011
ACTIZAL Pioglitazona Tableta IV Laboratorios Senisiain, S.A. de C.V. 5-oct-2016 MG 229M2011
MOPRO-D Pioglitazona Tableta IV Ultra Laboratorios, S.A. de C.V. 5-oct-2016 MG 231M2011
AGOPAR Pioglitazona Tableta IV Laboratorios Grin, S.A. de C.V. 5-oct-2016 MG 237M2011
GLIOZAC Pioglitazona Tableta IV Productos Maver, S.A. de C.V. 5-oct-2016 MG 238M2011
ZIANGLI Pioglitazona Tableta IV Serral, S.A. de C.V. 10-nov-2016 MG 280M2011
PIPTABAC Piperacilina / Tazobactam Solución IV Laboratorios Pisa, S.A. de C.V. 26-may-2016 MG 089M2011
REDEVANT Pitavastatina Tableta IV Eli Lilly y Compañía de México, S.A. de C.V. 4-jul-2016 MN 173M2011
DRAMIXOL Pramipexol Tableta IV Ultra Laboratorios, S.A. de C.V. 16-feb-2016 MG 031M2011
PREGEMAT Progesterona Emulsión IV Productos Científicos, S.A. de C.V. 7-ene-2016 MG 001M2011
Página 6 de 8 Diciembre 2011
7. Denominación distintiva Denominación genérica Forma farmacéutica
Clasificación
Artículo 226
LGS
Titular Vencimiento Clasificación
Registro
sanitario / SSA
PRILVER Ramipril Tableta IV Productos Maver, S.A. de C.V. 3-ago-2016 MG 193M2011
RESKISOF Risperidona Solución IV Laboratorios Pisa, S.A. de C.V. 3-feb-2016 MG 015M2011
RUPILIP Rosuvastatina Tableta IV Sandoz, S.A. de C.V. 4-ene-2017 MG 170M2011
ROSVADEN Rosuvastatina Tableta IV Laboratorios Alpharma, S.A. de C.V. 16-dic-2016 MG 331M2011
REPAFET Rupatadina Tableta IV Productos Científicos, S.A. de C.V. 12-may-2016 MN 084M2011
D-OKEN Sertralina Tableta IV
Winthrop Pharmaceuticals de México, S.A. de
C.V.
28-feb-2016 MG 040M2011
SEVAM Sevoflurano Solución IV Antibióticos de México, S.A. de C.V. 6-may-2016 MG 078M2011
LERK FLS Sildenafil Comprimido IV Siegfried Rhein, S.A. de C.V. 9-nov-2016 MG 265M2011
GO Sildenafil Tableta IV Laboratorios Liomont, S.A. de C.V. 8-nov-2016 MG 143M2011
EXZALTE Sildenafil Tableta I Lemery, S.A. de C.V. 3-nov-2016 MG 252M2011
GO Sildenafil Tableta IV Laboratorios Liomont, S.A. de C.V. 8-nov-2016 MG 253M2011
APODEFIL M Sildenafil Tableta IV Protein, S.A. de C.V. 8-nov-2016 MG 257M2011
MAZZOGRAN Sildenafil Tableta IV Productos Farmacéuticos Collins, S.A. de C.V. 8-nov-2016 MG 262M2011
LERK Sildenafil Tableta IV Siegfried Rhein, S.A. de C.V. 9-nov-2016 MG 263M2011
VISDONEC Sildenafil Tableta IV Laboratorios Alpharma, S.A. de C.V. 8-nov-2016 MG 266M2011
SFORZA Sildenafil Tableta IV Sandoz, S.A. de C.V. 9-nov-2016 MG 267M2011
G4 Sildenafil Tableta IV Pharmagen, S.A. de C.V. 8-nov-2016 MG 268M2011
SILCAREX Sildenafil Tableta IV Ultra Laboratorios, S.A. de C.V. 9-nov-2016 MG 273M2011
G4 Sildenafil Tableta IV Pharmagen, S.A. de C.V. 9-nov-2016 MG 274M2011
SINDEBAX Sildenafil Tableta IV Ranbaxy Laboratories Limited 16-nov-2016 MG 287M2011
BULLENZA Sildenafil Tableta IV Laboratorios Grin, S.A. de C.V. 23-nov-2016 MG 291M2011
SUBRIDION Sugammadex Solución IV Schering-Plough, S.A. de C.V. 1-ago-2016 MN 176M2011
ADCIRCA Tadalafil Tableta IV Eli Lilly y Compañía de México, S.A. de C.V. 12-dic-2016 MG 270M2011
PERPLAX Tamsulosina Cápsula IV Laboratorios Senisiain, S.A. de C.V. 7-abr-2016 MG 059M2011
NONDECEL Tamsulosina Cápsula IV Laboratorios Pisa, S.A. de C.V. 28-oct-2016 MG 247M2011
HEPTACIDIN Teicoplanina Solución IV Probiomed, S.A. de C.V. 18-mar-2016 MG 051M2011
BRILINTA Ticagrelor Tableta IV Astrazeneca, S.A. de C.V. 8-sep-2016 MN 216M2011
TOFIB Tobramicina Solución IV Productos Científicos, S.A. de C.V. 29-abr-2016 MG 064M2011
TOPUMATE Topiramato Tableta IV Serral, S.A. de C.V. 13-ene-2016 MG 010M2011
HULCIDOS Topiramato Tableta IV Lemery, S.A. de C.V. 11-feb-2016 MG 029M2011
TOPGRAN Topiramato Tableta IV Laboratorios Vanquish, S.A. de C.V. 26-may-2016 MG 081M2011
TORANEX Topotecán Solución IV Fresenius Kabi México, S.A. de C.V. 8-dic-2016 MR 167M2011
AMPROSEC Tramadol Solución IV Laboratorios Química Son's, S.A. de C.V. 16-feb-2016 MG 023M2011
MEGADOL Tramadol Solución IV Laboratorios Keton de México, S.A. de C.V. 28-feb-2016 MG 096M2011
TEMPOLIB Trimebutina Tableta IV Productos Medix, S.A de C.V. 12-jul-2016 MG 179M2011
Página 7 de 8 Diciembre 2011
8. Denominación distintiva Denominación genérica Forma farmacéutica
Clasificación
Artículo 226
LGS
Titular Vencimiento Clasificación
Registro
sanitario / SSA
VACUNA ANTIINFLUENZA
TRIVALENTE TIPO A Y B
Vacuna antiinfluenza trivalente Tipo A y
B
Suspensión IV
Laboratorios de Biológicos y Reactivos de
México, S.A. de C.V.
14-dic-2016 VA 210M2011
DOBVIR-MRL Vacuna anti-Sarampion y anti-Rubeola Suspensión IV Laboratorios Imperiales, S.A. de C.V. 28-mar-2016 VA 055M2011
PRIORIX-TETRA
Vacuna anti-sarampión, anti-parotiditid,
anti-varicela y anti-rubeola
Suspensión IV Glaxosmithkline México, S.A. de C.V. 12-abr-2016 VA 060M2011
FLUENZ
Vacuna trivalente antiinfluenza de virus
vivos atenuados tipo A y B
Solución IV Astrazeneca, S.A. de C.V. 6-may-2016 VA 075M2011
PASUATO Valproato de magnesio Solución IV Industrias Suanca, S.A. de C.V. 4-nov-2016 MG 209M2011
ACAVEXAL Valsartán Tableta IV Solara, S.A. de C.V. 8-nov-2016 MG 256M2011
MAZDA Venlafaxina Cápsula IV Laboratorios Pisa, S.A. de C.V. 3-ago-2016 MG 195M2011
ADEFAXIN Venlafaxina Cápsula IV Laboratorios Alpharma, S.A. de C.V. 21-dic-2016 MG 271M2011
QUIRALAM Zofenopril Tableta IV Dinafarma, S.A. de C.V. 24-ago-2016 MN 207M2011
COLEMEN Zofenopril Tableta IV Grimann, S.A. de C.V. 6-ene-2017 245M2011
Claves de Clasificación de Medicamentos:
MN Molécula Nueva
MG Medicamento Genérico
MB Medicamento biológico
MT Medicamentos biotecnológico
VA Vacuna
Página 8 de 8 Diciembre 2011